Abstracts tagged "autoantibodies and biomarkers"

Abstract Number: 722 • 2017 ACR/ARHP Annual Meeting
Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling
Peter Schulz-Knappe, Petra Budde and Hans-Dieter Zucht, Protagen AG, Dortmund, Germany
Background/Purpose: Early diagnosis as well as initiation of successful treatment are two big challenges in the management of patients with autoimmune diseases (AID). Overlap of…
Abstract Number: 1669 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondria DNA Antibody As an Improved Biomarker for Systemic Lupus Erythematosus
Yangsheng Yu¹, Kalika Mahato¹, Suyang Xu¹, Jenna Mu¹, Amanda Zhang¹, James R. O'Dell², Lynell W. Klassen², Michelene Hearth-Holmes³ and Kaihong Su¹, ¹Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ²Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, Univ. of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-dsDNA antibodies are highly specific for systemic lupus erythematosus (SLE) and often associate with lupus nephritis. Extracellular nucleosome DNA released from apoptotic or necrotic…
Abstract Number: 786 • 2013 ACR/ARHP Annual Meeting
Antibodies Against Drp-4 and Macropain Subunit C2 As a Potential Marker Of Aosd
Niklas T. Baerlecken¹, Nils Pursche², Torsten Witte³, Reinhold E. Schmidt¹, Marius Hoepfner¹, Frank Moosig⁴, Wolfgang L. Gross⁵, Eugen Feist⁶ and Dirk Foell⁷, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁵Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁷Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Making the diagnosis of adult-onset Still's disease (AOSD) is mainly based on the exclusion of inflammatory, infectious and malignant diseases. There are no specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].